However, the splenic immune cell populations after 7 days of treatment showed increased activation (CD25+, TIGIT+) of CD4+ T cells (Fig. S10E) when FGL2 activity was blocked, similar to what was observed in Fgl2−/− mice bearing B16F10 and ID8-p53−/−Brca2−/− tumours. The gene discussed is FGL2; the disease is neoplasm.